-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
The Oncology Institute Enrolls Nation’s First Two Patients in a Phase 3 Open-Label, Randomized Clinical Trial of Pirtobrutinib
The Oncology Institute Enrolls Nation’s First Two Patients in a Phase 3 Open-Label, Randomized Clinical Trial of Pirtobrutinib
Value-based Oncology Leader Improving Access to Cutting-Edge Therapies
CERRITOS, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), today announces the enrollment of two of its patients as the first and second patients dosed in the United States in a phase 3 open-label, randomized study of Pirtobrutinib (LOXO-305) versus Ibrutinib in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314). Pirtobrutinib (LOXO-305) is currently in clinical trial phase, whereas Ibrutinib has been available in the market since 2013. If approved, Pirtobrutinib (LOXO-305) aims to have better efficacy than other alternatives currently available. Benefits can include symptom reduction for patients. Eli Lilly and Company serves as the sponsor of this clinical trial.
Pirtobrutinib and Ibrutinib are both oral treatments that bind to the Bruton Tyrosine Kinase (BTK) protein to inhibit its activity. Ibrutinib, sold as Imbruvica, was first approved by the FDA in 2013.
Pirtobrutinib reversibly binds to BTK allowing for higher BTK inhibition and selectivity. This effect allows for the reduction of any off-target adverse effects. Other BTK inhibitors currently available in the market irreversibly bind to BTK. There is a growing concern about developing resistance to covalent BTK inhibitors, leading to treatment discontinuation in most patients. Researchers recognize Pirtobrutinib for its ability to treat recurrent or relapsing CLL.
Dr. Merrill Shum, TOI's Pharmacy Director, Sub Investigator and Treating Physician for this study, enrolled the patient in Whittier, California. His extensive experience includes being a lead principal investigator and sub-investigator in over 300 clinical trials and aiding in the FDA approval of several drugs.
Dr. John Khoury, one of TOI's Medical Directors, Sub Investigator and Treating Physician for this study, enrolled the patient in Glendale, California. He is the recipient of the 40 under 40 in Cancer Award and Freeman Wilner Foundation Compassionate care award. He has served as a Principal Investigator for multiple trials and has presented his research at many national conferences.
Dr. Richy Agajanian, TOI's Principal Investigator, leads this clinical trial. A dedicated and highly decorated physician, his past work includes cancer research that has contributed to developing new FDA-approved medications. Dr. Agajanian is also the Founder of The Oncology Institute.
"We at TOI are extremely proud of our role in this important clinical trial," says Dr. Yale Podnos, Chief Medical Officer of The Oncology Institute. "New, effective treatments can't be made available to the public without this important research. We look forward to working with the scientific community to continue to be at the forefront of cutting-edge oncology research."
TOI increases access to clinical trials by bringing this cutting-edge service into its 50+ community-based clinics. Currently TOI is conducting over 170 trials.
About The Oncology Institute, Inc.
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.7 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 90+ employed clinicians and more than 700 teammates in over 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit .
Media Contact
Julie Korinke
JulieKorinke@theoncologyinstitute.com
(562) 735-3226 x 88806
Juan Lezama
juanlezama@theoncologyinstitute.com
(562) 374-8434
Investor Relations
Solebury Trout
Maria Lycouris
investors@theoncologyinstitute.com
Value-based Oncology Leader Improving Access to Cutting-Edge Therapies
基于价值的肿瘤学领导者改善获得尖端疗法的机会
CERRITOS, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), today announces the enrollment of two of its patients as the first and second patients dosed in the United States in a phase 3 open-label, randomized study of Pirtobrutinib (LOXO-305) versus Ibrutinib in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314). Pirtobrutinib (LOXO-305) is currently in clinical trial phase, whereas Ibrutinib has been available in the market since 2013. If approved, Pirtobrutinib (LOXO-305) aims to have better efficacy than other alternatives currently available. Benefits can include symptom reduction for patients. Eli Lilly and Company serves as the sponsor of this clinical trial.
加利福尼亚州塞里托斯,9月2022年10月29日(环球网)--肿瘤研究所公司(纳斯达克市场代码:TOI)今天宣布,该公司的两名患者参加了在美国进行的第3期开放随机对照研究,即Pirtobrutinib(LOXO-305)与Ibrutinib治疗慢性淋巴细胞白血病/小淋巴细胞性淋巴瘤(Bruin-CLL-314)的首批和第二批患者。Pirtobrutinib(LOXO-305)目前处于临床试验阶段,而Ibrutinib自2013年以来一直在市场上销售。如果获得批准,Pirtobrutinib(LOXO-305)的目标是具有比现有其他替代品更好的疗效。好处可以包括减轻患者的症状。礼来公司是这项临床试验的赞助商。
Pirtobrutinib and Ibrutinib are both oral treatments that bind to the Bruton Tyrosine Kinase (BTK) protein to inhibit its activity. Ibrutinib, sold as Imbruvica, was first approved by the FDA in 2013.
Pirtobrutinib和Ibrutinib都是口服治疗,它们都与Bruton Tyroine Kinase(BTK)蛋白结合,以抑制其活性。Ibrutinib,以Imbrovica的名称销售,于2013年首次获得FDA批准。
Pirtobrutinib reversibly binds to BTK allowing for higher BTK inhibition and selectivity. This effect allows for the reduction of any off-target adverse effects. Other BTK inhibitors currently available in the market irreversibly bind to BTK. There is a growing concern about developing resistance to covalent BTK inhibitors, leading to treatment discontinuation in most patients. Researchers recognize Pirtobrutinib for its ability to treat recurrent or relapsing CLL.
Pirtobrutinib可逆地与BTK结合,允许更高的BTK抑制和选择性。这种效果可以减少任何偏离目标的不利影响。目前市场上可获得的其他BTK抑制剂不可逆转地与BTK结合。人们越来越担心对共价BTK抑制剂产生耐药性,导致大多数患者停止治疗。研究人员承认Pirtobrutinib治疗复发或复发的CLL的能力。
Dr. Merrill Shum, TOI's Pharmacy Director, Sub Investigator and Treating Physician for this study, enrolled the patient in Whittier, California. His extensive experience includes being a lead principal investigator and sub-investigator in over 300 clinical trials and aiding in the FDA approval of several drugs.
TAI‘s药房董事的Merrill Shum博士是这项研究的副研究员和治疗医生,他在加利福尼亚州惠蒂尔招募了这名患者。他的丰富经验包括在300多项临床试验中担任首席研究员和副研究员,并协助FDA批准几种药物。
Dr. John Khoury, one of TOI's Medical Directors, Sub Investigator and Treating Physician for this study, enrolled the patient in Glendale, California. He is the recipient of the 40 under 40 in Cancer Award and Freeman Wilner Foundation Compassionate care award. He has served as a Principal Investigator for multiple trials and has presented his research at many national conferences.
John Khoury博士是TOI的医学主任之一,也是这项研究的副研究员和治疗医生,他在加利福尼亚州的格伦代尔招募了这名患者。他是40岁以下癌症奖和弗里曼·威尔纳基金会同情关怀奖的获得者。他曾担任多项试验的首席调查员,并在许多国家会议上介绍了他的研究成果。
Dr. Richy Agajanian, TOI's Principal Investigator, leads this clinical trial. A dedicated and highly decorated physician, his past work includes cancer research that has contributed to developing new FDA-approved medications. Dr. Agajanian is also the Founder of The Oncology Institute.
TOI的首席研究员里希·阿加贾尼安博士领导了这项临床试验。作为一名敬业和备受赞誉的医生,他过去的工作包括癌症研究,这些研究为开发FDA批准的新药做出了贡献。阿加贾尼安博士也是肿瘤研究所的创始人。
"We at TOI are extremely proud of our role in this important clinical trial," says Dr. Yale Podnos, Chief Medical Officer of The Oncology Institute. "New, effective treatments can't be made available to the public without this important research. We look forward to working with the scientific community to continue to be at the forefront of cutting-edge oncology research."
肿瘤研究所首席医疗官Yale Podnos博士说:“我们TOI为我们在这项重要的临床试验中所扮演的角色感到非常自豪。如果没有这项重要的研究,就无法向公众提供新的、有效的治疗方法。我们期待着与科学界合作,继续走在前沿肿瘤学研究的前沿。
TOI increases access to clinical trials by bringing this cutting-edge service into its 50+ community-based clinics. Currently TOI is conducting over 170 trials.
TOI将这项尖端服务引入其50多家社区诊所,从而增加了临床试验的机会。目前,TOI正在进行170多项试验。
About The Oncology Institute, Inc.
肿瘤学研究所简介
Founded in 2007, TOI is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.7 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 90+ employed clinicians and more than 700 teammates in over 50 clinic locations and growing, TOI is changing oncology for the better. For more information visit .
TOI成立于2007年,通过在社区环境中提供高度专业化的、基于价值的癌症护理来推动肿瘤学的发展。TOI为大约170万患者提供基于证据的尖端癌症护理,包括临床试验、输血和其他传统上与最先进的护理提供机构相关的护理提供模式。TOI拥有90多名受雇的临床医生和50多个诊所的700多名队友,而且还在不断增长,TOI正在让肿瘤学变得更好。有关更多信息,请访问。
Media Contact
Julie Korinke
JulieKorinke@theoncologyinstitute.com
(562) 735-3226 x 88806
媒体联系人
朱莉·科林克
邮箱:JulieKorinke@theoncologyInstitute te.com
(562) 735-3226 x 88806
Juan Lezama
juanlezama@theoncologyinstitute.com
(562) 374-8434
胡安·莱扎马
邮箱:juanlezama@theoncologyInstitute te.com
(562) 374-8434
Investor Relations
Solebury Trout
Maria Lycouris
investors@theoncologyinstitute.com
投资者关系
索尔伯里鲑鱼
玛丽亚·吕库利斯
邮箱:Investors@theoncologyInstitute te.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧